<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02679287</url>
  </required_header>
  <id_info>
    <org_study_id>18617</org_study_id>
    <secondary_id>R01DK085623</secondary_id>
    <nct_id>NCT02679287</nct_id>
  </id_info>
  <brief_title>Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control</brief_title>
  <official_title>Project Nightlight: Efficacy and System Acceptance of Dinner/Night vs. 24hr Closed Loop Control</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Diagnostic Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>TypeZero Technologies, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tandem Diabetes Care, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DexCom, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to use an investigational type of technology called Closed-Loop
      Control (CLC) Medical Platform System to help control blood sugar in people with type 1
      diabetes mellitus in a home setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CLC is an &quot;artificial pancreas&quot; (AP) application that uses advanced closed loop control
      algorithms to automatically manage blood glucose levels for people with Type 1 Diabetes. The
      system modulates insulin to keep blood glucose in a targeted range. The CLC will be deployed
      with different functionalities at different stages of the trial, resulting in variation in
      what the subject will be responsible for and what the system will drive.These functionalities
      occur in a randomized cross-over design, each occurring for 8 weeks. These modalities are:

        1. SAP=sensor-augmented pump only

        2. USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting
           at dinner and continuing overnight

        3. USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time &lt;70 mg/dl by CGM</measure>
    <time_frame>8 weeks</time_frame>
    <description>Overnight CLC achieved by USS+SAP(d) (also known at Evening-Night CLC) will be superior to SAP alone in terms of reduced incidence and risk for hypoglycemia overnight without deterioration in hemoglobin A1c. Outcomes will be stratified by Hemoglobin A1c &lt; 7.5% vs ≥7.5% and time of day.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>8 weeks</time_frame>
    <description>Overnight CLC achieved by USS+SAP(d) (also known as Evening-Night CLC) will be superior to SAP alone in terms of reduced incidence and risk for hypoglycemia overnight without deterioration in hemoglobin A1c. Outcomes will be stratified by Hemoglobin A1c &lt; 7.5% vs ≥7.5% and time of day.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time Between 70-180 mg/dL by CGM</measure>
    <time_frame>8 weeks</time_frame>
    <description>Time in target range 70-180 mg/dL measured by CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time &gt;180 mg/dL by CGM</measure>
    <time_frame>8 weeks</time_frame>
    <description>Time in hyperglycemia range &gt;180 mg/dL measured by CGM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Glucose by CGM</measure>
    <time_frame>8 weeks</time_frame>
    <description>Mean glucose measured by CGM overall in mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Blood Glucose Index (LBGI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Index measure of low blood glucose risk. This is an index that indicates risk of hypoglycemia with low values indicating lower risk of hypoglycemia (particularly values 1 or lower).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Blood Glucose Index (HBGI)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Index measure of high blood glucose risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGM &lt;70mg/dL</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percentage time &lt;70mg/dL measured by CGM in three study phases combining Group A and B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin A1c by Study Session</measure>
    <time_frame>8 weeks</time_frame>
    <description>Hemoglobin A1c after each 8 weeks study session by Group A and Group B.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)
SAP=sensor-augmented pump only
USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight
USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP
SAP=sensor-augmented pump only
USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight
USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CLC</intervention_name>
    <description>The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Closed Loop Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  type 1 diabetes for at least one year

          -  using insulin for at least 1 year

          -  an insulin pump for at least 6 months

          -  willingness to switch to lispro (Humalog) or aspart (Novolog) if using glulisine
             (Apidra).

        Exclusion Criteria:

          -  a medical condition or being been treated with medications that might interfere with
             the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sue A. Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UVA Center for Diabetes Technology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Virginia Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>February 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2016</study_first_posted>
  <results_first_submitted>April 6, 2020</results_first_submitted>
  <results_first_submitted_qc>June 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 9, 2020</results_first_posted>
  <last_update_submitted>June 5, 2020</last_update_submitted>
  <last_update_submitted_qc>June 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Sue Brown</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Closed-Loop Control (CLC)</keyword>
  <keyword>Sensor-Augmented Therapy (SAP)</keyword>
  <keyword>USS Virginia</keyword>
  <keyword>Continuous Glucose Monitor (CGM)</keyword>
  <keyword>Insulin Pump</keyword>
  <keyword>Artificial Pancreas (AP)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Generally will be available after publications completed.</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02679287/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>103 participants signed informed consent and were assessed for eligibility.10 were excluded prior to randomization (7 did not meet inclusion criteria, 2 declined to participate, 1 lost to followup). 93 participants were randomized and assigned to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A</title>
          <description>Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)
CLC: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
SAP=sensor-augmented pump only
USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight
USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control</description>
        </group>
        <group group_id="P2">
          <title>Group B</title>
          <description>Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP
CLC: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
SAP=sensor-augmented pump only
USS+SAP (d)= Evening and Overnight Closed-Loop Control=SAP during day and CLC starting at dinner and continuing overnight
USS+CLC (d)= 24/7 Closed-Loop Control=24-hour Day and Night Closed Loop Control</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Randomization-Study Session 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Regimen not compatible with study</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Work or scheduling conflict</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disliked mobile system</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event prior to intervention</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Work/Scheduling Conflict</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disliked Mobile System</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Work/Scheduling Conflict</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Phase 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analyzed group includes participants who completed two study sessions or more.</population>
      <group_list>
        <group group_id="B1">
          <title>Group A</title>
          <description>Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)
CLC: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.</description>
        </group>
        <group group_id="B2">
          <title>Group B</title>
          <description>Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP
CLC: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.7" spread="13.5"/>
                    <measurement group_id="B2" value="41.9" spread="10.1"/>
                    <measurement group_id="B3" value="42.3" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Caucasian/More than One Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.6" spread="1.08"/>
                    <measurement group_id="B2" value="7.24" spread="0.97"/>
                    <measurement group_id="B3" value="7.42" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time &lt;70 mg/dl by CGM</title>
        <description>Overnight CLC achieved by USS+SAP(d) (also known at Evening-Night CLC) will be superior to SAP alone in terms of reduced incidence and risk for hypoglycemia overnight without deterioration in hemoglobin A1c. Outcomes will be stratified by Hemoglobin A1c &lt; 7.5% vs ≥7.5% and time of day.</description>
        <time_frame>8 weeks</time_frame>
        <population>This primary analysis was confined to the phase of the study comparing SAP to Evening-Night CLC only when combining group A and B. Data on 24/7 CLC phase is included in secondary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A and Group B Combined</title>
            <description>Order of interventions for Group A 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)
Order of intervention for Group B 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP
SAP=Sensor-augmented pump (study CGM+personal pump) USS+SAP(d)=Evening-Overnight CLC USS+CLC= 24/7 CLC
CLC: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.</description>
          </group>
        </group_list>
        <measure>
          <title>Time &lt;70 mg/dl by CGM</title>
          <description>Overnight CLC achieved by USS+SAP(d) (also known at Evening-Night CLC) will be superior to SAP alone in terms of reduced incidence and risk for hypoglycemia overnight without deterioration in hemoglobin A1c. Outcomes will be stratified by Hemoglobin A1c &lt; 7.5% vs ≥7.5% and time of day.</description>
          <population>This primary analysis was confined to the phase of the study comparing SAP to Evening-Night CLC only when combining group A and B. Data on 24/7 CLC phase is included in secondary outcomes.</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CGM Time&lt;70 mg/dL in SAP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGM Time&lt;70 mg/dL in Evening-Overnight CLC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that there is no difference in percentage of time &lt;70 mg/dL in SAP vs. evening-overnight CLC session. Change in HbA1c during study sessions was used as a covariate of the model.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>2.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin A1c</title>
        <description>Overnight CLC achieved by USS+SAP(d) (also known as Evening-Night CLC) will be superior to SAP alone in terms of reduced incidence and risk for hypoglycemia overnight without deterioration in hemoglobin A1c. Outcomes will be stratified by Hemoglobin A1c &lt; 7.5% vs ≥7.5% and time of day.</description>
        <time_frame>8 weeks</time_frame>
        <population>This primary analysis was confined to the phase of the study comparing SAP to Evening-Night CLC only when combining group A and B and included the baseline HbA1c and final HbA1c. Data on HbA1c by study phase is included in secondary outcomes.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A and Group B Combined</title>
            <description>Order of interventions for Group A 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)
Order of intervention for Group B 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP
SAP=Sensor-augmented pump (study CGM+personal pump) USS+SAP(d)=Evening-Overnight CLC USS+CLC= 24/7 CLC
CLC: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c</title>
          <description>Overnight CLC achieved by USS+SAP(d) (also known as Evening-Night CLC) will be superior to SAP alone in terms of reduced incidence and risk for hypoglycemia overnight without deterioration in hemoglobin A1c. Outcomes will be stratified by Hemoglobin A1c &lt; 7.5% vs ≥7.5% and time of day.</description>
          <population>This primary analysis was confined to the phase of the study comparing SAP to Evening-Night CLC only when combining group A and B and included the baseline HbA1c and final HbA1c. Data on HbA1c by study phase is included in secondary outcomes.</population>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" spread="1.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HbA1c at end of study</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.11" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time Between 70-180 mg/dL by CGM</title>
        <description>Time in target range 70-180 mg/dL measured by CGM</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sensor-augmented Pump Therapy (SAP)</title>
            <description>Use of study CGM and personal pump for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Evening and Overnight Closed-Loop Control</title>
            <description>Use of CLC evening to overnight hours for two sessions of 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>24/7 Closed-Loop Control</title>
            <description>Use of CLC 24/7 for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time Between 70-180 mg/dL by CGM</title>
          <description>Time in target range 70-180 mg/dL measured by CGM</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" spread="14.6"/>
                    <measurement group_id="O2" value="67.6" spread="12.9"/>
                    <measurement group_id="O3" value="69.5" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time &gt;180 mg/dL by CGM</title>
        <description>Time in hyperglycemia range &gt;180 mg/dL measured by CGM</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sensor-augmented Pump Therapy (SAP)</title>
            <description>Use of study CGM and personal pump for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Evening and Overnight Closed-Loop Control</title>
            <description>Use of CLC evening to overnight hours for two sessions of 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>24/7 Closed-Loop Control</title>
            <description>Use of CLC 24/7 for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Time &gt;180 mg/dL by CGM</title>
          <description>Time in hyperglycemia range &gt;180 mg/dL measured by CGM</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.4" spread="16.5"/>
                    <measurement group_id="O2" value="30.1" spread="13.7"/>
                    <measurement group_id="O3" value="28.7" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Glucose by CGM</title>
        <description>Mean glucose measured by CGM overall in mmol/L</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sensor-augmented Pump Therapy (SAP)</title>
            <description>Use of study CGM and personal pump for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Evening and Overnight Closed-Loop Control</title>
            <description>Use of CLC evening to overnight hours for two sessions of 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>24/7 Closed-Loop Control</title>
            <description>Use of CLC 24/7 for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Glucose by CGM</title>
          <description>Mean glucose measured by CGM overall in mmol/L</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" spread="1.58"/>
                    <measurement group_id="O2" value="8.82" spread="1.22"/>
                    <measurement group_id="O3" value="8.74" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Blood Glucose Index (LBGI)</title>
        <description>Index measure of low blood glucose risk. This is an index that indicates risk of hypoglycemia with low values indicating lower risk of hypoglycemia (particularly values 1 or lower).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sensor-augmented Pump Therapy (SAP)</title>
            <description>Use of study CGM and personal pump for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Evening and Overnight Closed-Loop Control</title>
            <description>Use of CLC evening to overnight hours for two sessions of 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>24/7 Closed-Loop Control</title>
            <description>Use of CLC 24/7 for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Low Blood Glucose Index (LBGI)</title>
          <description>Index measure of low blood glucose risk. This is an index that indicates risk of hypoglycemia with low values indicating lower risk of hypoglycemia (particularly values 1 or lower).</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" spread="0.79"/>
                    <measurement group_id="O2" value="0.66" spread="0.42"/>
                    <measurement group_id="O3" value="0.57" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Blood Glucose Index (HBGI)</title>
        <description>Index measure of high blood glucose risk.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sensor-augmented Pump Therapy (SAP)</title>
            <description>Use of study CGM and personal pump for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Evening and Overnight Closed-Loop Control</title>
            <description>Use of CLC evening to overnight hours for two sessions of 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>24/7 Closed-Loop Control</title>
            <description>Use of CLC 24/7 for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>High Blood Glucose Index (HBGI)</title>
          <description>Index measure of high blood glucose risk.</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.82" spread="4.61"/>
                    <measurement group_id="O2" value="6.97" spread="3.52"/>
                    <measurement group_id="O3" value="6.53" spread="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CGM &lt;70mg/dL</title>
        <description>Percentage time &lt;70mg/dL measured by CGM in three study phases combining Group A and B.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sensor-augmented Pump Therapy (SAP)</title>
            <description>Use of study CGM and personal pump for 8 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Evening and Overnight Closed-Loop Control</title>
            <description>Use of CLC evening to overnight hours for two sessions of 8 weeks</description>
          </group>
          <group group_id="O3">
            <title>24/7 Closed-Loop Control</title>
            <description>Use of CLC 24/7 for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>CGM &lt;70mg/dL</title>
          <description>Percentage time &lt;70mg/dL measured by CGM in three study phases combining Group A and B.</description>
          <units>Percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="77"/>
                <count group_id="O3" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="3.3"/>
                    <measurement group_id="O2" value="2.3" spread="1.7"/>
                    <measurement group_id="O3" value="1.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin A1c by Study Session</title>
        <description>Hemoglobin A1c after each 8 weeks study session by Group A and Group B.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A</title>
            <description>Order of intervention will be 1) SAP; 2) USS + SAP(d); 3) USS +CLC (d); 4) USS + SAP(d)
CLC: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.</description>
          </group>
          <group group_id="O2">
            <title>Group B</title>
            <description>Order of intervention will be 1)USS + SAP(d) ; 2)USS +CLC (d); 3) USS + SAP(d); 4) SAP
CLC: The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c by Study Session</title>
          <description>Hemoglobin A1c after each 8 weeks study session by Group A and Group B.</description>
          <units>percentage of glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Session 1 (Group A SAP; Group B evening-night CLC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="0.83"/>
                    <measurement group_id="O2" value="7.01" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 2 (Gp A Evening-NIght CLC;Gp B 24/7 CLC)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.12" spread="0.79"/>
                    <measurement group_id="O2" value="6.95" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 3 (Gp A 24/7 CLC; Gp B evening-night CLC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.13" spread="0.8"/>
                    <measurement group_id="O2" value="7.06" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Session 4 (Gp A Evening-Night CLC; Gp B SAP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="0.73"/>
                    <measurement group_id="O2" value="7.12" spread="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 10-11 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Sensor-Augmented Pump Therapy (SAP)</title>
          <description>8 week study phase for both Group A and Group B that underwent the same procedures in different orders.</description>
        </group>
        <group group_id="E2">
          <title>Evening and Overnight Closed-Loop Control</title>
          <description>8 week study phases (2) for both Group A and Group B that underwent the same procedures in different orders.</description>
        </group>
        <group group_id="E3">
          <title>24/7 Closed-Loop Control</title>
          <description>8 week study phase for both Group A and Group B that underwent the same procedures in different orders.</description>
        </group>
        <group group_id="E4">
          <title>Other</title>
          <description>This includes any study periods outside of other study phases listed such as screening and washout periods for both Group A and Group B that underwent the same procedures in different orders.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Renal Cell Carcinoma with Surgical Resection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip Replacement Surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="93"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="93"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Hypoglycemia</sub_title>
                <description>Hypoglycemia requiring the assistance of a third party.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Hyperglycemia with ketosis not meeting diabetes ketoacidosis criteria</sub_title>
                <description>Significantly elevated ketones requiring intervention without meeting DCCT criteria for diabetic ketoacidosis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>New onset Crohn's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections requiring medications or interventions</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="93"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
              <event>
                <sub_title>Conditions requiring steroid use</sub_title>
                <description>e.g. cervical radiculopathy, knee injury, tenosynovitis, dermatitis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Outpatient surgery or procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="93"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>New onset edema requiring medications</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="93"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sue Brown, MD</name_or_title>
      <organization>University of Virginia</organization>
      <phone>434-982-0602</phone>
      <email>sab2f@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

